Gene therapy kept vision working in mice with a rare inherited eye disease
☕ Includes a question for the family ↓
Gene and cell therapiesPart of a story we are following · 4 articles · See every update
Here is some encouraging news for families living with rare inherited eye diseases. Scientists have shown that gene therapy, given as one injection into the eye, can keep vision working in mice with a genetic condition that normally damages the retina. This has not been tested in people yet.
In a study of mice with a mild form of Zellweger spectrum disorder, a single gene therapy injection under the retina improved vision, and the benefits lasted 6 months. The abstract does not say how many mice were studied.
How the study worked
Researchers used mice that carry the mouse version of the most common harmful gene change found in people with this disorder. They gave the mice one injection under the retina, carrying a working copy of a gene called PEX1, and tested several doses. They then checked vision and eye health over 6 months. The work was published in Mol Ther on November 12, 2026. It is an early laboratory study in mice, the step that comes before any trial in people.
What is Zellweger spectrum disorder?
Zellweger spectrum disorder is a rare genetic condition. It is caused by changes in a family of genes called PEX genes. These genes are needed to build and run peroxisomes, tiny structures inside your cells that the body needs to work normally.
Because these genes are active all over the body, the disorder can affect many systems, including the eyes. In the retina, the light-sensing layer at the back of the eye, it causes vision loss that gets worse over time.
The abstract notes that there are no proven treatments aimed at the cause of this disorder. Scientists also did not know whether fixing the problem in the eye alone would be enough to protect sight. This study gives a clear answer in mice: it was.
What they found
The gene therapy worked on several fronts at once. Compared with untreated mice with the same condition, the treated mice showed better results in all of these:
- Functional vision, meaning how well the mice could actually use their eyesight
- Retinal response, meaning how well the retina answered to light
- The structure of the photoreceptors, the cells that catch light
- The health of the retinal pigment epithelium, the supporting layer behind those cells
- Inflammation under the retina
- Peroxisome-related chemicals in the eye, which moved in the right direction
The improvements held up to the end of the study, 6 months after the single injection. That matters, because a treatment that fades quickly would not be much use for a lifelong condition.
This team had already shown in earlier work that a first version of the treatment improved how the retina responded. This time they used a re-designed, clinically relevant version and measured many more things. The results point the same way, and they are broader and stronger.
The authors describe the study as preclinical proof of concept. In plain words, it shows that replacing the missing gene only in the eye can ease vision loss in this kind of inherited eye disease.
What does this mean for people?
The abstract does not report any study in people, and it does not say that this treatment has been approved by the FDA. It is not approved yet. The next steps would be further safety work and then trials in people, and the abstract does not give a timeline.
Still, the result is a real step forward. The treatment was built in a clinically relevant way, and it protected both how the eye works and how it looks under the microscope. Findings like this are what researchers need before they can move toward people.
What you can do today
Nothing about your own care needs to change today, because this therapy is not available yet. If you want to follow the topic, spend a few minutes on the National Eye Institute website (nei.nih.gov) reading about inherited retinal diseases and how gene therapy for the eye works.
For clinicians and researchers
Design: Preclinical dose-range study of a re-designed AAV8-delivered HsPEX1 subretinal gene therapy in a mouse model of mild Zellweger spectrum disorder (homozygous PEX1-p.[Gly844Asp]), with a single subretinal injection and endpoint at 6 months.
Main result: Significant improvement was reported in functional vision, retinal response, photoreceptor structure, retinal pigment epithelium integrity, subretinal inflammation and peroxisomal metabolites, durable to 6 months. The abstract gives no effect sizes or confidence intervals.
Main limitation: Mouse model of mild disease with a 6-month endpoint; findings are preclinical and do not establish safety or efficacy in patients. Treatment was localized to the retina.
Open question: Whether localized retinal restoration of peroxisome function translates to patients with Zellweger spectrum disorder, and whether benefit persists beyond 6 months, remains untested.
Talk about it at home
Inside the back of your eye is a layer called the retina, a bit like the sensor in a camera that catches light and turns it into a picture for your brain. In some inherited eye diseases, the cells there are missing a working page from their recipe book, so they slowly stop doing their job. In this study, scientists gave mice a tiny delivery of the missing page, then watched their eyes for months and found the retina stayed healthier than in mice that did not get it.
Try it at home
Ask a grandparent or an older neighbor how eye checkups worked when they were young, and whether they remember the day someone noticed they needed glasses.
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. Gene therapy kept vision working in mice with a rare inherited eye disease. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/mongevity-tech/2026/11/gene-therapy-preserves-vision-mice-zellweger-eye-disease/Mongevity Desk. Gene therapy kept vision working in mice with a rare inherited eye disease [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/mongevity-tech/2026/11/gene-therapy-preserves-vision-mice-zellweger-eye-disease/Mongevity Desk. (2026, November 21). Gene therapy kept vision working in mice with a rare inherited eye disease. Mongevity. https://mongevity.science/mongevity-tech/2026/11/gene-therapy-preserves-vision-mice-zellweger-eye-disease/
<a href="https://mongevity.science/mongevity-tech/2026/11/gene-therapy-preserves-vision-mice-zellweger-eye-disease/">Gene therapy kept vision working in mice with a rare inherited eye disease</a>
Free to share or quote with credit and a link.
Questions and answers
- Can people get this gene therapy now?
- No. It has only been tested in mice, and it is not approved yet. People would need to be studied in trials first.
- What did the gene therapy do in the mice?
- One injection under the retina delivered a working copy of the PEX1 gene. Vision, the retina's response, and the structure of light-sensing cells all improved.
- How long did the benefit last?
- The improvements lasted to the end of the study, 6 months after the single injection.
- What is Zellweger spectrum disorder?
- It is a rare genetic condition caused by changes in PEX genes. It can affect many parts of the body, including the retina, where it causes progressive vision loss.


